Those 71 EAP Adult patients at 63% survival mean Ryoncil will get up, we just cant endure a lengthy delay.
Cost cutting strategy explains why George bought on market- no cap raise until we get our share price up with some good news like trial length, recruitment won't be an issue.
Re the 71 patients - that's $35,000,000 plus in sales if we were approved and that's after all else has failed!
Good buying at the moment
Market is working out that Ryoncil has received manufacturing approval and the lot used in 001 has been stamped for efficacy- that's huge
Reg
Mesoblast CC Transcript 31/8, page-13
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.010(0.69%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.49 | $1.44 | $3.472M | 2.379M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12398 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 5440 | 3 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |